Arrowhead's new obesity-focused subsidiary set for early clinical entry
This article was originally published in Scrip
Arrowhead Research has set up a new company to commercialise a platform technology for use in developing treatments for weight-loss and obesity-related metabolic conditions. Ablaris Therapeutics hopes to have a drug candidate in the clinic in 2011.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.